Investor FAQs

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the 13th leading cause of death in the United States.

Endologix currently employs 345 people as of March 31, 2011.

December 31

Endologix is listed on the NASDAQ exchange, and the trading symbol is ELGX.

Endologix became public through a reverse merger in May 2002.

As of March 31, 2011, there were 56.1 million shares of common stock outstanding.

Endologix does not currently issue dividends.

Endologix does not currently have a direct stock-purchase plan.

PricewaterhouseCoopers, LLP
2020 Main Street, Suite 400
Irvine, CA 92614

American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038

Stradling Yocca Carlson & Rauth
660 Newport Center Drive
Newport Beach, CA 92660
(949) 725-4000

We are located in Southern California. Our address is:
11 Studebaker
Irvine, CA 92618

Please submit your question using the form below. * Required fields

Name *
Email *
Subject *
Comments *
Type in number *
	This helps Endologix prevent automated submissions.